| Document Date: 2014-03-04 03:02:34
Open Document File Size: 667,28 KBShare Result on Facebook
City Utrecht / Berlin / / Company IgG / ProBioGen AG / Merus B.V. / / Country Germany / Netherlands / / / Event Business Partnership / / IndustryTerm biotechnology company developing cancer therapeutics / clonal manufacturing cell line / heterodimerization technology / optimized biopharmaceutical products / technology royalty-free / enhancement technology / media platform / manufacturing requirements / fucose-engineering technology / smart and flexible solutions / / MedicalCondition thereby eliminating tumor / Tumor / cancer / hematological malignancies / solid tumors / diseases / fully-integrated biotechnology company developing cancer / Merus’ promising bispecific cancer / / MedicalTreatment cancer therapeutics / / Organization Contract Development and Manufacturing Organization / FDA / / Person Ludger Wess / Ines-Regina Buth / Volker Sandig / Mark Throsby / / / Position Chief Scientific Officer / designer / Gabriele Schneider Vice President Business Development ProBioGen AG / producer / / Product GlymaxX / / Technology antibodies / biotechnology / CH3 heterodimerization technology / ADCC Enhancement Technology / fucose-engineering technology / GlymaxX technology / / URL www.merus.nl / www.glymaxx.com / www.probiogen.de / /
SocialTag |
PRESS RELEASE ProBioGen and Merus Sign Deal on GlymaxX® ADCC Enhancement Technology - GlymaxX® Manufacturing Technology Improves Bispecific Antibody Activity for Solid Tumor Treatment Berlin, Germany, and Utrecht,